AM Pharma
  • Home
  • About Us
    • About AM-Pharma
    • Management Team
    • Supervisory Board
    • Careers
  • Our approach
    • Our Product and MOA
    • Acute Kidney Injury (AKI)
    • Our AKI Pipeline
      • SA-AKI
      • COVID-19 and AKI
      • CKD and AKI
      • CSA-AKI
  • Partnering
  • Investors
  • Media Centre
    • Press Releases
    • Publications
  • Contact
  • Menu Menu

Home > Our approach > Sepsis-associated acute kidney injury

Sepsis-associated acute kidney injury

Our goal is to develop and commercialize our proprietary recombinant human alkaline phosphatase therapeutic to transform the treatment prospects for patients with Sepsis-Associated Acute Kidney Injury (SA-AKI) – a devastating disease with high mortality rates and no approved pharmacological treatments, affecting millions of patients worldwide.

Urgent medical need

Acute kidney injury (AKI) is an acute inflammation of the kidney, which impairs the kidney function. It involves inflammatory processes in the kidney which may result in the need for dialysis. If the patient survives, the damage may not always be reversible and can even lead to complete loss of renal function, requiring kidney replacement. Hospital‐acquired AKI affects annually around 3 million patients in Europe, the US and Japan, and is associated with mortality in roughly 700,000 patients. It occurs in 40-60% of critical care admissions. Depending on the severity and cause of renal injury, mortality ranges from 10% to as high as 60%. In the US alone, hospitals spend around $10 billion each year on managing this major medical problem. The most important causes of AKI are sepsis, cardiovascular surgery, exposure to nephrotoxic drugs and trauma.

Patients with AKI have reduced alkaline phosphatase levels and activity in the kidneys. Alkaline phosphatase is a common endogenous enzyme present in many cells and organs (e.g. intestines, placenta, liver, bone, kidney and granulocytes). AM-Pharma has developed a novel recombinant human alkaline phosphatase as a medicinal product to be used via intravenous injection for the treatment of sepsis-associated acute kidney injury (SA-AKI). The recombinant alkaline phosphatase is an optimized recombinant human alkaline phosphatase with high stability and high activity.

AM-Pharma has shown that a short-term treatment with recombinant alkaline phosphatase helps protect kidney function in AKI, which can be classified as a disease modifying anti-inflammatory effect. Currently the only treatment option is dialysis and supportive care and no drugs are approved to treat AKI. Typically, these patients are treated in Intensive Care Units, often with support of nephrologists.

With no drugs currently approved to treat the condition, recombinant alkaline phosphatase could become the first pharmacological treatment for critically ill AKI patients.

Clinical Studies

Phase III Study update

We are conducting our Phase III REVIVAL pivotal study, a randomized, double-blind, placebo-controlled, two-arm, parallel-group, multi-center trial to evaluate the efficacy and safety of our proprietary human recombinant alkaline phosphatase for the treatment of patients with SA-AKI. The study will enroll approximately 1400 patients with SA-AKI in the main study population. In two exploratory cohorts, up to 100 patients with moderate Chronic Kidney Disease (CDK) and up to 100 patients with COVID-19 will be enrolled. The primary aim of the study is to confirm the improvement on the primary endpoint of 28-day all-cause mortality, as observed in the Phase II STOP-AKI study. Secondary endpoints include the treatment effect on long-term Major Adverse Kidney Events (MAKE), on the use of organ support, length of stay in the ICU and on 90-day all-cause mortality. Further information on this study can be found at www.clinicaltrials.gov, NCT04411472 (REVIVAL).

Revival Logo
  • Privacy Policy
© AM-Pharma B.V.
Website by BTTR
linkedin
Scroll to top

We use cookies to help us improve our website by collecting and reporting information on how you use it. For more information about how we use cookies please see our Cookies Policy

AcceptReject


How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only